Shopping Cart 0
Cart Subtotal
USD 0

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca (Dry Eye)-Pipeline Review, H2 2018, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca (Dry Eye)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 31, 5, 1, 32, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Keratoconjunctivitis Sicca (Dry Eye)-Overview 6

Keratoconjunctivitis Sicca (Dry Eye)-Therapeutics Development 7

Keratoconjunctivitis Sicca (Dry Eye)-Therapeutics Assessment 20

Keratoconjunctivitis Sicca (Dry Eye)-Companies Involved in Therapeutics Development 30

Keratoconjunctivitis Sicca (Dry Eye)-Drug Profiles 48

Keratoconjunctivitis Sicca (Dry Eye)-Dormant Projects 205

Keratoconjunctivitis Sicca (Dry Eye)-Discontinued Products 209

Keratoconjunctivitis Sicca (Dry Eye)-Product Development Milestones 210

Appendix 218


List Of Figure

List of Figures

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Allergan Plc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Ascendia Pharmaceuticals LLC, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Aurinia Pharmaceuticals Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by BioLineRx Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Cambium Medical Technologies LLC, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Clementia Pharmaceuticals Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Dompe Farmaceutici SpA, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by HanAll Biopharma Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Huons Global Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Icure Pharmaceutical Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Kala Pharmaceuticals Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Kv1.3 Therapeutics, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Laboratoires Thea SA, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Laboratorios Sophia SA de CV, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Merck & Co Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Mitotech SA, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Nanomerics Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Nemus Bioscience Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Novaliq GmbH, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Ocular Therapeutix Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Oculis ehf, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Ocunova LLC, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by OncoNOx ApS, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Otsuka Holdings Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Palatin Technologies Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Pharmaleads SA, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Quorum Innovations LLC, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Redwood Pharma AB, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Samjin Pharm Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Senju Pharmaceutical Co Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Shire Plc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Sylentis SAU, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Tetra Bio-Pharma Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by TopiVert Ltd, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Vanda Pharmaceuticals Inc, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Pipeline by Xigen SA, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Dormant Projects, H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Dormant Projects, H2 2018 (Contd..1), H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Dormant Projects, H2 2018 (Contd..2), H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Dormant Projects, H2 2018 (Contd..3), H2 2018

Keratoconjunctivitis Sicca (Dry Eye)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Keratoconjunctivitis sicca (Dry Eye) Therapeutic Products under Development, Key Players in Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Keratoconjunctivitis sicca (Dry Eye) Pipeline Overview, Keratoconjunctivitis sicca (Dry Eye) Pipeline, Keratoconjunctivitis sicca (Dry Eye) Pipeline Assessment


Companies

Aldeyra Therapeutics Inc

Allergan Plc

Ascendia Pharmaceuticals LLC

Aurinia Pharmaceuticals Inc

BioLineRx Ltd

Cambium Medical Technologies LLC

Clementia Pharmaceuticals Inc

Dompe Farmaceutici SpA

HanAll Biopharma Co Ltd

Huons Global Co Ltd

Icure Pharmaceutical Inc

Kala Pharmaceuticals Inc

Kukje Pharmaceutical Industry Co Ltd

Kv1.3 Therapeutics

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Merck & Co Inc

Mitotech SA

Nanomerics Ltd

Nemus Bioscience Inc

Novaliq GmbH

Ocular Therapeutix Inc

Oculis ehf

Ocunova LLC

OncoNOx ApS

Otsuka Holdings Co Ltd

Palatin Technologies Inc

Pharmaleads SA

Quorum Innovations LLC

Redwood Pharma AB

RegeneRx Biopharmaceuticals Inc

Samjin Pharm Co Ltd

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sylentis SAU

Tetra Bio-Pharma Inc

TopiVert Ltd

Vanda Pharmaceuticals Inc

Xigen SA